UA84420C2 - СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК - Google Patents

СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК

Info

Publication number
UA84420C2
UA84420C2 UAA200510644A UAA200510644A UA84420C2 UA 84420 C2 UA84420 C2 UA 84420C2 UA A200510644 A UAA200510644 A UA A200510644A UA A200510644 A UAA200510644 A UA A200510644A UA 84420 C2 UA84420 C2 UA 84420C2
Authority
UA
Ukraine
Prior art keywords
benzoic acid
nonsense
modulation
treating
acid compounds
Prior art date
Application number
UAA200510644A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Гари Митчелл Карп
Сеонгвоо Хванг
Гуангминг Чен
Нил Грегори Альмстенд
Янг-Чун Мун
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК. filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of UA84420C2 publication Critical patent/UA84420C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UAA200510644A 2003-04-11 2004-04-09 СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК UA84420C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46198803P 2003-04-11 2003-04-11
PCT/US2004/011106 WO2004091502A2 (en) 2003-04-11 2004-04-09 1,2,4-oxadiazole benzoic acid compounds

Publications (1)

Publication Number Publication Date
UA84420C2 true UA84420C2 (ru) 2008-10-27

Family

ID=33299886

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200510644A UA84420C2 (ru) 2003-04-11 2004-04-09 СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК

Country Status (29)

Country Link
US (17) US6992096B2 (enExample)
EP (9) EP3178816A1 (enExample)
JP (2) JP4851933B2 (enExample)
KR (1) KR101134188B1 (enExample)
CN (2) CN104056278B (enExample)
AU (1) AU2004229487B9 (enExample)
BE (1) BE2015C025I2 (enExample)
BR (1) BRPI0409319B8 (enExample)
CA (1) CA2521992C (enExample)
CR (1) CR8086A (enExample)
CY (7) CY1115870T1 (enExample)
DK (7) DK3345895T3 (enExample)
EA (1) EA009120B1 (enExample)
ES (7) ES2528195T3 (enExample)
FR (1) FR15C0030I2 (enExample)
HU (7) HUE055056T2 (enExample)
IL (2) IL171343A (enExample)
LU (1) LU92698I2 (enExample)
MA (1) MA27802A1 (enExample)
MX (1) MXPA05010747A (enExample)
NO (2) NO332843B1 (enExample)
NZ (1) NZ543263A (enExample)
PL (7) PL3889142T3 (enExample)
PT (7) PT3345895T (enExample)
SI (7) SI3103800T1 (enExample)
TR (1) TR201706226T4 (enExample)
UA (1) UA84420C2 (enExample)
WO (1) WO2004091502A2 (enExample)
ZA (1) ZA200508298B (enExample)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
AU2003247610A1 (en) * 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US7927791B2 (en) * 2002-07-24 2011-04-19 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mRNA decay
PT3345895T (pt) 2003-04-11 2020-01-29 Ptc Therapeutics Inc Composto de ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e tratamento de doenças
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
CA2583177A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
PL1874306T3 (pl) * 2005-04-08 2012-11-30 Ptc Therapeutics Inc Kompozycje zawierające 1,2,4-oksadiazol aktywny po podaniu doustnie w celu supresyjnego leczenia niesensownej mutacji
AU2012238226B2 (en) * 2005-04-08 2015-05-14 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
CN100378084C (zh) * 2005-08-01 2008-04-02 安徽大学 2,5-二芳基取代基-1,3,4-噁二唑衍生物及其合成方法、用途
TWI426905B (zh) * 2006-02-09 2014-02-21 Enzon Pharmaceuticals Inc 用於乳癌、大腸直腸癌、胰臟癌、卵巢癌及肺癌之治療的７-乙基-１０羥喜樹鹼之多臂聚合性共軛物
JP5367563B2 (ja) * 2006-03-30 2013-12-11 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス突然変異を有するｄｎａからの機能的タンパク質の産生のための方法及びそれと関連した障害の治療
NZ571869A (en) * 2006-04-06 2011-11-25 Prosidion Ltd Heterocyclic GPCR agonists
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PL2674428T3 (pl) 2006-04-07 2017-01-31 Vertex Pharmaceuticals Incorporated Modulatory transporterów z kasetą wiążącą ATP
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2007130499A2 (en) * 2006-05-01 2007-11-15 Virobay, Inc. Antiviral agents
ZA200901782B (en) * 2006-09-08 2010-06-30 Ptc Therapeutics Inc Processes for the preparation of 1, 2, 4-oxadiazole benzoic acids
WO2008130370A1 (en) * 2006-09-25 2008-10-30 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
CN104341371A (zh) * 2006-09-25 2015-02-11 Ptc医疗公司 3-[5-(2-氟苯基)-[1,2,4]噁二唑-3-基]-苯甲酸的晶型
AU2016262645B2 (en) * 2006-10-12 2018-05-17 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
PL2073805T3 (pl) * 2006-10-12 2015-08-31 Ptc Therapeutics Inc Sposoby dawkowania 1,2,3-oksadiazolu aktywnego po podaniu doustnym w terapii supresyjnej mutacji nonsensownej
AU2013219243B2 (en) * 2006-10-12 2016-09-08 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
NZ577111A (en) * 2006-12-15 2012-05-25 Abbott Lab Novel oxadiazole compounds
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
EP2142498A2 (en) * 2007-04-02 2010-01-13 Institute for Oneworld Health Cftr inhibitor compounds and uses thereof
CN101965344B (zh) * 2007-06-22 2013-03-06 弗·哈夫曼-拉罗切有限公司 异*唑-咪唑衍生物
EP2167508A1 (en) * 2007-07-23 2010-03-31 Summit Corporation Plc Compounds for treating duchenne muscular dystrophy
PE20090510A1 (es) 2007-08-03 2009-05-22 Summit Corp Plc Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
JP5762743B2 (ja) 2007-08-13 2015-08-12 モンサント テクノロジー エルエルシー 線虫を制御するための組成物および方法
BRPI0817597A2 (pt) 2007-10-04 2015-04-07 Merck Serono Sa Compostos de diarila de oxadiazol, processo para sua preparação, composições farmacêuticas e kit compreendendo os mesmos, bem como seus usos
ES2622423T3 (es) * 2007-10-04 2017-07-06 Merck Serono S.A. Derivados de oxadiazol
AU2008310734B2 (en) * 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
DK2578571T3 (en) 2007-11-16 2015-10-05 Vertex Pharma Isoquinoline modulators of ATP binding cassette transporters
KR20100097195A (ko) * 2007-12-07 2010-09-02 애보트 게엠베하 운트 콤파니 카게 ５－할로겐－치환된 옥스인돌 유도체 및 바소프레신－의존성 질병을 치료하기 위한 이의 용도
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
LT3170818T (lt) 2007-12-07 2020-05-25 Vertex Pharmaceuticals Incorporated Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
EP2623504A1 (de) * 2007-12-07 2013-08-07 Abbott GmbH & Co. KG 5,6-Disubstituierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
ES2398676T3 (es) * 2007-12-07 2013-03-20 Abbott Gmbh & Co. Kg Derivados de oxindol sustituidos con amidometilo y su uso para la producción de un medicamento para el tratamiento de enfermedades dependientes de la vasopresina
JP5451633B2 (ja) * 2007-12-21 2014-03-26 メルク セローノ ソシエテ アノニム トリアゾールオキサジアゾール誘導体
TWI415607B (zh) * 2007-12-25 2013-11-21 Kissei Pharmaceutical 新穎兒茶酚衍生物、含有其之醫藥組成物及該等之用途
EP2732819B1 (en) 2008-02-07 2019-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
AU2009231993B2 (en) 2008-03-31 2013-10-10 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
US8207205B2 (en) * 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131952A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising thiazole derivatives
US20090264481A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Oxadiazole Derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090264471A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazole Derivatives
EP2684873B1 (en) * 2008-06-09 2019-01-16 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
AU2009271328B2 (en) * 2008-06-24 2012-09-06 Irm Llc Compounds and methods for modulating G protein-coupled receptors
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
HUE025314T2 (en) 2009-02-10 2016-02-29 Monsanto Technology Llc Preparations and procedures for controlling nematodes
JP5620129B2 (ja) * 2009-03-19 2014-11-05 富士フイルム株式会社 光学フィルム、位相差板、楕円偏光板、液晶表示装置、及び化合物
RU2398770C1 (ru) * 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2251437B1 (en) 2009-05-13 2013-12-04 Hannelore Breitenbach-Koller Method for identifying compounds that control the translational activity of ribosomal proteins in differential mRNA expression
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
AR076984A1 (es) 2009-06-08 2011-07-20 Merck Serono Sa Derivados de pirazol oxadiazol
US9849146B2 (en) * 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
EP2462276B1 (en) * 2009-08-05 2014-11-05 International Paper Company Dry fluff pulp sheet additive
JP5650233B2 (ja) 2009-11-13 2015-01-07 レセプトス インコーポレイテッドＲｅｃｅｐｔｏｓ， Ｉｎｃ． 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法
ES2665461T3 (es) * 2009-11-13 2018-04-25 Celgene International Ii Sàrl Moduladores del receptor esfingosina 1-fosfato y métodos de síntesis quiral
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
US20110251253A1 (en) 2010-03-25 2011-10-13 Vertex Pharmaceuticals Incorporated Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
RS62767B1 (sr) 2010-04-07 2022-01-31 Vertex Pharma Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
EP3045452A1 (en) 2010-04-22 2016-07-20 Vertex Pharmaceuticals Inc. Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
ES2710854T3 (es) 2010-08-05 2019-04-29 Univ Lille Compuesto útil para el tratamiento de enfermedades mediadas por una mutación sin sentido y composición farmacéutica que comprende dicho compuesto
EP2608779A2 (en) 2010-08-23 2013-07-03 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
WO2012158550A2 (en) 2011-05-13 2012-11-22 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
CA2838529C (en) 2011-06-07 2020-03-24 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
US20140094465A1 (en) * 2011-06-10 2014-04-03 N30 Pharmaceuticals, Inc. Compounds as S-Nitrosoglutathione Reductase Inhibitors
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR101314488B1 (ko) * 2011-09-08 2013-10-07 중앙대학교 산학협력단 신경줄기세포 분화조절제용 신규 옥사디아졸 유도체 및 이의 의학적 용도
US9254291B2 (en) 2011-11-08 2016-02-09 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
LT2806859T (lt) 2012-01-25 2019-10-25 Vertex Pharma 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzenkarboksirūgšties kompozicijos
US9598395B2 (en) 2012-03-23 2017-03-21 The Regents Of The University Of California Premature-termination-codons readthrough compounds
ES2675588T3 (es) 2012-05-29 2018-07-11 Parion Sciences, Inc. Dendrímero como aminoamidas que posee actividad de bloqueador de canal de sodio para el tratamiento del ojo seco y otras enfermedades mucosas
DK2867230T3 (da) 2012-07-02 2020-04-14 Monsanto Technology Llc Fremgangsmåde til fremstilling af 3,5-disubstitueret 1,2,4-oxadiazoler
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
SMT201800590T1 (it) 2012-11-02 2019-01-11 Vertex Pharma Composizioni farmaceutiche per il trattamento di malattie mediate da cftr
JP6076498B2 (ja) 2012-12-13 2017-02-08 ノバルティス アーゲー ナンセンス突然変異抑制剤としてのピリミド［４，５−ｂ］キノリン−４，５（３ｈ，１０ｈ）−ジオン
NZ709197A (en) 2012-12-17 2020-06-26 Parion Sciences Inc 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
PL3925607T3 (pl) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
US9896448B2 (en) 2014-06-03 2018-02-20 Novartis Ag Pyrimido[4,5-b]quinoline-4,5(3H, 10H)-dione derivatives
SG11201609209YA (en) 2014-06-03 2016-12-29 Novartis Ag Naphthyridinedione derivatives
WO2015186061A1 (en) 2014-06-03 2015-12-10 Novartis Ag Pyridopyrimidinedione derivatives
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
IL313498A (en) 2014-10-06 2024-08-01 Vertex Pharma Modulators of the cystic fibrosis transmembrane conductance regulator
CN104292180A (zh) * 2014-10-12 2015-01-21 湖南华腾制药有限公司 一种恶二唑衍生物的制备方法
US10174012B2 (en) 2014-11-04 2019-01-08 The University Of Kansas LKB1-AMPK activators for therapeutic use in polycystic kidney disease
WO2016073545A1 (en) * 2014-11-06 2016-05-12 Concert Pharmaceuticals, Inc. Phenyloxadiazole benzoic acids
JP6596090B2 (ja) * 2014-12-17 2019-10-23 キングス カレッジ ロンドン レチノイン酸受容体ベータ（ＲＡＲβ）アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技（台州）有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
US10517853B2 (en) * 2015-10-30 2019-12-31 Ptc Therapeutics, Inc. Methods for treating epilepsy
US20200262800A1 (en) 2015-11-16 2020-08-20 Ptc Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxadiazole benzoic acid compounds, compositions and uses thereof
JP2019502753A (ja) 2015-12-23 2019-01-31 ムーンショット ファーマ エルエルシー ナンセンス変異依存ｍＲＮＡ分解機構の抑制による免疫応答の誘導法
TW201808922A (zh) 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
CN106279057B (zh) * 2016-08-15 2022-04-15 广州明药科技有限公司 Ataluren的合成方法
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
EP3512516A1 (en) 2016-09-13 2019-07-24 Marco Cipolli Method of treatment of shwachman-diamond syndrome
WO2018187479A1 (en) 2017-04-04 2018-10-11 Case Western Reserve University Method of modulating ribonucleotide reductase
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
US11795196B2 (en) 2017-12-15 2023-10-24 Stealth Biotherapeutics Inc. Mitochondria-targeting peptides
WO2020078894A1 (en) 2018-10-15 2020-04-23 Academisch Medisch Centrum Oncotherapeutic combinations
KR102658031B1 (ko) 2018-12-27 2024-04-18 제이투에이치바이오텍 (주) 근이영양증의 치료 또는 예방에 유용한 화합물 및 이들의 의약 용도의 치료, 개선 또는 예방용 유도체
CA3135641A1 (en) 2019-04-10 2020-10-15 Ptc Therapeutics, Inc. Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients
CN110987847B (zh) * 2019-12-11 2021-02-19 苏州今蓝纳米科技有限公司 1,3,4-噁二唑衍生物在检测酸以及数据加密和储存中的应用
CN111675672A (zh) * 2020-05-12 2020-09-18 石家庄市度智医药科技有限公司 一种制备阿塔鲁伦的方法
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies
CN116217508B (zh) * 2022-12-15 2024-12-17 浙江工业大学 一类用于保护β细胞来治疗II型糖尿病的噁二唑类化合物及其制备方法和应用
US11932632B1 (en) 2023-10-13 2024-03-19 King Faisal University N'-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzo[d][1,3]dioxole-5 carboximidamide as an antimicrobial compound
US11958814B1 (en) 2023-11-02 2024-04-16 King Faisal University 3-(4-nitrophenyl)-5-((2-isopropyl-5-methylphenoxy)methyl)-1,2,4-oxadiazole as an anti-cancer and antimicrobial compound
CN119638642A (zh) * 2023-12-12 2025-03-18 暨南大学 双环类化合物及其药物组合物和应用
WO2025243250A1 (en) * 2024-05-23 2025-11-27 Biophore India Pharmaceuticals Pvt. Ltd. A process for the preparation of 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291628A (enExample) 1962-04-17
US3325446A (en) * 1964-04-17 1967-06-13 Allied Chem Stabilized halogen-containing olefin polymer compositions and stabilizers therefor
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4022901A (en) 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
JPS51143669A (en) 1975-06-06 1976-12-10 Takeda Chem Ind Ltd A process for preparing 1,2,4- oxadiazole derivatives
US4016170A (en) * 1975-07-28 1977-04-05 Sandoz, Inc. Oxadiazolyl benzamides
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4166732A (en) * 1977-05-12 1979-09-04 Monsanto Company Oxadiazol-5-yl-benzoates
US4135910A (en) 1977-05-12 1979-01-23 Monsanto Company Oxadiazol-3-yl-benzoates as plant growth regulants
US4165910A (en) * 1977-10-25 1979-08-28 Bunker Ramo Corporation Electrical connector
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4268299A (en) 1978-08-17 1981-05-19 Monsanto Company Method and composition for plant growth regulation containing trifluoromethyl 1,3,4 oxadiazol benzoates
US4210762A (en) 1978-08-17 1980-07-01 Monsanto Company 2[5-(3-Trifluoromethylphenyl)-1,3,4-oxadiazol-2-yl] benzoates
DE3173083D1 (en) * 1980-03-22 1986-01-16 Fbc Ltd Pesticidal heterocyclic compounds, processes for preparing them, compositions containing them, and their use
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4320801A1 (de) 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
TW343965B (en) 1994-03-30 1998-11-01 Hoffmann La Roche Novel mono- and bicyclic DNA gyrase inhibitors
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6071700A (en) 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
WO1996028205A1 (en) 1995-03-14 1996-09-19 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosing unit
ZA962078B (en) 1995-03-14 1996-09-25 Siemens Ag Ultrasonic atomizer device with removable precision dosating unit
CZ66498A3 (cs) 1995-09-07 1998-07-15 Novartis Ag Substituované fosfinové kyseliny, způsoby jejich přípravy, farmaceutický prostředek, který je obsahuje, a jejich použití
WO1997039745A1 (en) 1996-04-19 1997-10-30 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the prevention of cancer
CN1216534A (zh) * 1996-04-26 1999-05-12 日本曹达株式会社 杂环取代的新颖苯衍生物和除草剂
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
AU712057B2 (en) 1996-06-07 1999-10-28 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
US6034106A (en) 1996-06-07 2000-03-07 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity
DE19626318A1 (de) 1996-07-01 1998-01-08 Basf Ag Farbstoffmischungen, enthaltend Polyazofarbstoffe
ZA98371B (en) 1997-01-31 1999-07-16 Du Pont Genetically transformed plants demonstrating resistance to porphyrinogen biosynthesis-inhibiting herbicides.
WO1998045263A1 (en) 1997-04-07 1998-10-15 Georgetown University Analogs of cocaine
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
WO1999021852A1 (en) * 1997-10-27 1999-05-06 Nippon Soda Co., Ltd. Novel benzoylpyrazole derivatives and herbicides
NZ506289A (en) 1998-03-16 2004-12-24 Nektar Therapeutics Aerosolized active agent delivery to the lungs at a flow rate of less than 17 liters per minute
AU750369B2 (en) 1998-04-23 2002-07-18 Cortech, Inc. Cysteine protease inhibitors
HUP0104280A3 (en) 1998-10-08 2002-07-29 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors, process for their preparation, medicaments containing them
ATE259803T1 (de) 1998-10-09 2004-03-15 Janssen Pharmaceutica Nv 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung
AU1455500A (en) 1998-10-29 2000-05-22 Trega Biosciences, Inc. Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
HUP0104768A3 (en) 1998-12-23 2002-05-28 Smithkline Beecham Corp 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
AU3196100A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
AU3196200A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Beta-amino acid derivatives
AU3196300A (en) 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Carbocyclic sulfonamide derivatives
CN1356977A (zh) 1999-05-17 2002-07-03 诺沃挪第克公司 胰高血糖素拮抗剂/反向激动剂
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
JP2001247569A (ja) 1999-08-12 2001-09-11 Japan Tobacco Inc ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2001066534A2 (en) 2000-03-09 2001-09-13 Abbott Laboratories Cyclic and bicyclic diamino histamine-3 receptor antagonists
US6465444B2 (en) 2000-03-22 2002-10-15 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
WO2001083464A1 (en) * 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders
GB0011089D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
BR0111206A (pt) 2000-05-22 2003-04-15 Aventis Pharma Inc Derivados de arilmetilamina para uso como inibidores de triptase
CN1328143A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——人甲基化－dna－蛋白－半胱氨酸甲基转移酶13和编码这种多肽的多核苷酸
JP2002105073A (ja) 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
AUPR362001A0 (en) 2001-03-08 2001-04-05 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2342432A1 (en) 2001-03-28 2002-09-28 Christopher Norbert Johnson Novel compound
GB0108102D0 (en) * 2001-03-30 2001-05-23 Pfizer Ltd Compounds
DE50204780D1 (de) 2001-04-19 2005-12-08 Bayer Healthcare Ag Arylsulfonamide als antivirale mittel
AU2002313633B2 (en) * 2001-06-08 2007-03-01 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
JP2003081832A (ja) * 2001-06-26 2003-03-19 Takeda Chem Ind Ltd レチノイド関連受容体機能調節剤
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
NZ538339A (en) 2002-08-09 2007-01-26 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
CA2495179A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
MXPA05010456A (es) 2003-03-28 2006-03-21 Pfizer Prod Inc Compuestos de quinolina y quinoxalina.
PT3345895T (pt) * 2003-04-11 2020-01-29 Ptc Therapeutics Inc Composto de ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e tratamento de doenças
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
WO2005060961A2 (en) 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
CA2583177A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
PL1874306T3 (pl) * 2005-04-08 2012-11-30 Ptc Therapeutics Inc Kompozycje zawierające 1,2,4-oksadiazol aktywny po podaniu doustnie w celu supresyjnego leczenia niesensownej mutacji
JP5367563B2 (ja) 2006-03-30 2013-12-11 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス突然変異を有するｄｎａからの機能的タンパク質の産生のための方法及びそれと関連した障害の治療
WO2007123848A2 (en) 2006-04-19 2007-11-01 Brown University Therapeutic compositions containing modified class i slrp proteins
ZA200901782B (en) * 2006-09-08 2010-06-30 Ptc Therapeutics Inc Processes for the preparation of 1, 2, 4-oxadiazole benzoic acids
CN104341371A (zh) 2006-09-25 2015-02-11 Ptc医疗公司 3-[5-(2-氟苯基)-[1,2,4]噁二唑-3-基]-苯甲酸的晶型
PL2073805T3 (pl) 2006-10-12 2015-08-31 Ptc Therapeutics Inc Sposoby dawkowania 1,2,3-oksadiazolu aktywnego po podaniu doustnym w terapii supresyjnej mutacji nonsensownej
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2009023509A2 (en) 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
ES2622423T3 (es) 2007-10-04 2017-07-06 Merck Serono S.A. Derivados de oxadiazol
CA2704049A1 (en) 2007-10-26 2009-04-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2234625B8 (en) 2007-12-17 2013-10-30 The Regents of the University of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
AU2009271328B2 (en) 2008-06-24 2012-09-06 Irm Llc Compounds and methods for modulating G protein-coupled receptors
HUE038428T2 (hu) 2008-10-07 2018-10-29 Horizon Orphan Llc Aeroszol fluorokinolon készítmények javított farmakokinetika érdekében
RU2398770C1 (ru) 2009-03-27 2010-09-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Меченная тритием 3-[5-(2-фторфенил)-1,2,4-оксадиазол-3-ил]бензойная кислота

Also Published As

Publication number Publication date
NO2015002I1 (no) 2015-02-16
WO2004091502A8 (en) 2005-11-24
US7202262B2 (en) 2007-04-10
HUE055434T2 (hu) 2021-11-29
EP1618098A4 (en) 2008-07-16
EP3345895A1 (en) 2018-07-11
ES2887054T3 (es) 2021-12-21
PT3103800T (pt) 2018-07-27
KR101134188B1 (ko) 2012-04-12
EP3889142A1 (en) 2021-10-06
KR20060009838A (ko) 2006-02-01
CY1122659T1 (el) 2020-10-14
US20140301978A1 (en) 2014-10-09
US7772259B2 (en) 2010-08-10
IL225161A (en) 2014-03-31
FR15C0030I1 (enExample) 2015-05-22
EP2910551A1 (en) 2015-08-26
BRPI0409319B8 (pt) 2021-05-25
SI3103800T1 (sl) 2018-10-30
DK3103800T3 (en) 2018-07-30
ES2624610T3 (es) 2017-07-17
EP3103800A1 (en) 2016-12-14
SI1618098T1 (sl) 2015-04-30
EP3632902A1 (en) 2020-04-08
PL3549936T3 (pl) 2021-11-08
US20100121070A1 (en) 2010-05-13
US20050164973A1 (en) 2005-07-28
EP1618098B1 (en) 2014-11-19
EP1618098A2 (en) 2006-01-25
HUE047569T2 (hu) 2020-04-28
NO332843B1 (no) 2013-01-21
BRPI0409319A (pt) 2006-04-25
US20120178080A1 (en) 2012-07-12
NO20055314L (no) 2006-01-04
PT3889142T (pt) 2022-08-22
US20100168109A1 (en) 2010-07-01
ES2679108T3 (es) 2018-08-22
PL2910551T3 (pl) 2017-09-29
JP2011251981A (ja) 2011-12-15
HK1093979A1 (en) 2007-03-16
US7419991B2 (en) 2008-09-02
US20150148346A1 (en) 2015-05-28
EP3178816A1 (en) 2017-06-14
EA009120B1 (ru) 2007-10-26
CY1125544T1 (el) 2024-09-20
ES2926542T3 (es) 2022-10-26
CN1802360B (zh) 2014-05-07
PL3632902T3 (pl) 2021-12-20
US8017636B2 (en) 2011-09-13
US20070161687A1 (en) 2007-07-12
BRPI0409319B1 (pt) 2019-11-12
HUE059464T2 (hu) 2022-11-28
CN1802360A (zh) 2006-07-12
LU92698I2 (fr) 2015-06-22
US20060148863A1 (en) 2006-07-06
PL3889142T3 (pl) 2022-09-26
CY1115870T1 (el) 2016-06-22
US20110311486A1 (en) 2011-12-22
PT3632902T (pt) 2021-09-15
BE2015C025I2 (enExample) 2023-08-09
JP4851933B2 (ja) 2012-01-11
CN104056278B (zh) 2017-01-18
CN104056278A (zh) 2014-09-24
HK1257517A1 (en) 2019-10-25
PT3345895T (pt) 2020-01-29
CA2521992C (en) 2013-02-05
SI2910551T1 (sl) 2017-07-31
US8486982B2 (en) 2013-07-16
JP2006522826A (ja) 2006-10-05
CY1124464T1 (el) 2022-07-22
US20060148864A1 (en) 2006-07-06
EP3889142B1 (en) 2022-06-15
PT2910551T (pt) 2017-05-22
US8227494B2 (en) 2012-07-24
AU2004229487A1 (en) 2004-10-28
EP4101846B1 (en) 2023-08-02
US20120277234A1 (en) 2012-11-01
CY1120446T1 (el) 2019-07-10
EA200501601A1 (ru) 2006-06-30
US7304080B2 (en) 2007-12-04
EP4101846A1 (en) 2022-12-14
DK3889142T3 (da) 2022-09-12
US9861617B2 (en) 2018-01-09
MA27802A1 (fr) 2006-03-01
NO20055314D0 (no) 2005-11-10
CY1119001T1 (el) 2018-01-10
US8129540B2 (en) 2012-03-06
FR15C0030I2 (fr) 2015-07-24
MXPA05010747A (es) 2006-05-25
US20180092887A1 (en) 2018-04-05
HK1202254A1 (en) 2015-09-25
PT3549936T (pt) 2021-07-14
EP2910551B1 (en) 2017-02-15
US8299105B2 (en) 2012-10-30
SI3345895T1 (sl) 2020-03-31
US20100216851A1 (en) 2010-08-26
HUE039026T2 (hu) 2018-12-28
IL171343A (en) 2013-06-27
AU2004229487B9 (en) 2010-06-10
EP3549936A1 (en) 2019-10-09
PL3103800T3 (pl) 2018-11-30
SI3632902T1 (sl) 2022-01-31
US20160081988A1 (en) 2016-03-24
PL1618098T3 (pl) 2015-04-30
US8975287B2 (en) 2015-03-10
AU2004229487B2 (en) 2010-05-20
WO2004091502A2 (en) 2004-10-28
ES2528195T3 (es) 2015-02-05
US9205088B2 (en) 2015-12-08
JP5436500B2 (ja) 2014-03-05
NO2015002I2 (no) 2015-02-03
US10071081B2 (en) 2018-09-11
DK3345895T3 (da) 2020-02-03
CR8086A (es) 2006-12-19
ZA200508298B (en) 2007-01-31
EP3345895B1 (en) 2019-12-04
US7683082B2 (en) 2010-03-23
PL3345895T3 (pl) 2020-05-18
NZ543263A (en) 2008-12-24
DK3632902T3 (da) 2021-09-13
SI3889142T1 (sl) 2022-10-28
US20130289007A1 (en) 2013-10-31
EP3632902B1 (en) 2021-07-14
WO2004091502A3 (en) 2004-12-29
HUS1500021I1 (hu) 2017-04-28
US20040204461A1 (en) 2004-10-14
SI3549936T1 (sl) 2021-09-30
CY2015017I2 (el) 2016-06-22
DK1618098T3 (en) 2015-01-12
US8163782B2 (en) 2012-04-24
TR201706226T4 (tr) 2018-06-21
EP3103800B1 (en) 2018-06-13
HUE055056T2 (hu) 2021-10-28
ES2770035T3 (es) 2020-06-30
HK1214253A1 (en) 2016-07-22
ES2881198T3 (es) 2021-11-29
PT1618098E (pt) 2015-02-10
DK3549936T3 (da) 2021-07-12
US6992096B2 (en) 2006-01-31
HUE031794T2 (en) 2017-08-28
US8796322B2 (en) 2014-08-05
CA2521992A1 (en) 2004-10-28
US20060035943A1 (en) 2006-02-16
CY2015017I1 (el) 2016-06-22
EP3549936B1 (en) 2021-06-02
DK2910551T3 (en) 2017-05-15

Similar Documents

Publication Publication Date Title
UA84420C2 (ru) СОЕДИНЕНИЯ 1,2,4-ОКСАДИАЗОЛБЕНЗОЙНОЙ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ СОЕДИНЕНИЙ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, СВЯЗАННОГО С ПРЕЖДЕВРЕМЕННОЙ ТЕРМИНАЦИЕЙ ТРАНСЛЯЦИИ ИЛИ НОНСЕНС-ОБУСЛОВЛЕННЫМ УМЕНЬШЕНИЕМ мРНК
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
SE0001899D0 (sv) New compounds
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
GEP20125565B (en) Lactam compounds and their pharmaceutical use
IL164974A0 (en) Novel compounds and their use
GEP20074197B (en) 5ht2c receptor modulators
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
WO2004009549A3 (en) Piperidines useful for the treatment of central nervous system disorders
AP2000001929A0 (en) Substituted indolealkanoic acids.
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MX2009003160A (es) Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol -3-il]-benzoico.
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
DE60110054D1 (en) Cardioprotektive phosphonate
WO2006124012A3 (en) Compounds for treating alzheimer&#39;s disease and for inhibiting beta-amyloid peptide production
EE200400031A (et) Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat
DE602004014937D1 (de) Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
ZA200001596B (en) α, β-unsaturated ketones.
IL165220A0 (en) Novel compounds, their use and preparation
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
IL149544A0 (en) N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR Xa
BR0314821A (pt) Derivado de piperidina, composição farmacêutica, uso do derivado de piperidina, e, método para tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou uma condição de um corpo animal vivo